Physician profile
John P Lundin
NPI 1033114467
$1,462.74
in general payments reported to CMS, 2019-2025
14 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.42 · 2020: $26.63 · 2021: $126 · 2022: $188 · 2023: $417 · 2024: $274 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $444.95 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $269.52 | 2023-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $157.60 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $125.16 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $115.03 | 2023-2025 | Verquvo, Capvaxive |
| Edwards Lifesciences Corporation | $69.67 | 2021-2025 | |
| Baxter Healthcare | $68.20 | 2022 | |
| Medtronic, INC. | $53.48 | 2021-2025 | Corevalve Evolut R, Linq II |
| Abiomed | $49.11 | 2025 | |
| Janssen Pharmaceuticals, INC | $43.48 | 2021-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $22.23 | 2024 | |
| Alnylam Pharmaceuticals INC. | $16.08 | 2025 | Onpattro |
| Novo Nordisk INC | $14.58 | 2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.65 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lundin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.